Suomi -
suomi -
Fimea (Suomen lääkevirasto)
sevelamer pharmathen 800 mg tabletti, kalvopäällysteinen
pharmathen s.a. - sevelamer carbonate - tabletti, kalvopäällysteinen - 800 mg - sevelameeri
Euroopan unioni -
suomi -
EMA (European Medicines Agency)
tukysa
seagen b.v. - tucatinib - breast neoplasms; neoplasm metastasis - antineoplastiset aineet - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑her2 treatment regimens.
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
aripiprazole accord healthcare 5 mg tabletti
accord healthcare b.v. accord healthcare b.v. - aripiprazolum - tabletti - 5 mg - aripipratsoli
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
aripiprazole accord healthcare 10 mg tabletti
accord healthcare b.v. accord healthcare b.v. - aripiprazolum - tabletti - 10 mg - aripipratsoli
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
aripiprazole accord healthcare 15 mg tabletti
accord healthcare b.v. accord healthcare b.v. - aripiprazolum - tabletti - 15 mg - aripipratsoli
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
aripiprazole accord healthcare 30 mg tabletti
accord healthcare b.v. accord healthcare b.v. - aripiprazolum - tabletti - 30 mg - aripipratsoli
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
rasagiline accord healthcare 1 mg tabletti
accord healthcare b.v. accord healthcare b.v. - rasagilini tartras - tabletti - 1 mg - rasagiliini
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
cytarabine accord healthcare 20 mg/ml injektio/infuusioneste, liuos
accord healthcare b.v. - cytarabine - injektio/infuusioneste, liuos - 20 mg/ml - sytarabiini
Euroopan unioni -
suomi -
EMA (European Medicines Agency)
pyrukynd
agios netherlands b.v. - mitapivat sulfate - genetic diseases, inborn; anemia, hemolytic - other hematological agents - pyrukynd is indicated for the treatment of pyruvate kinase deficiency (pk deficiency) in adult patients (see section 4.
Euroopan unioni -
suomi -
EMA (European Medicines Agency)
celsentri
viiv healthcare b.v. - maravirokia - hiv-infektiot - antiviraalit systeemiseen käyttöön - celsentri, in combination with other antiretroviral medicinal products, is indicated for treatment experienced adults, adolescents and children of 2 years of age and older and weighing at least 10 kg infected with only ccr5-tropic hiv-1 detectable,.